BUSINESS

• Sobi’s PNH Drug to Hit Japan Market on Sept. 4, Taiho's FGFR Inhibitor on Sept. 7
  August 31, 2023

• Novartis Rolls Out Luxturna in Japan, 2 Treatment Facilities Selected
  August 31, 2023

• Sandoz Completes Acquisition of Astellas’ Antifungal Mycamine
  August 31, 2023

• Toray to Kick Off Antibody PII Studies for Gastric Cancer
  August 31, 2023

• Takeda Snags Japan Rights to ImmunoGen’s ADC
  August 30, 2023

• Shionogi Rolls Out Flomox Fine Granules for Children in China
  August 30, 2023

• First 10 Drugs Named for Medicare Price Negotiations, None from Japan Firms
  August 30, 2023

• Oral Flu Drug Prescriptions 11 Times More than Pre-COVID: July Survey
  August 29, 2023

• Nichi-Iko Winds Up Avastin Biosimilar Deal with Sandoz
  August 29, 2023

• Pfizer Gets Breast, Ovarian Cancer Nod for Avastin Biosimilar
  August 29, 2023

• Taiho Gets Options to French Firm’s GnT-V-Targeted Cancer Drug in Asia
  August 28, 2023

• FDA Grants Priority Review for Xtandi in Earlier Type of Prostate Cancer
  August 25, 2023

• Ayumi Walks Away from JPMA, Plans to Join JGA
  August 23, 2023

• Mounjaro Makes Comeback as No 1 in GP Promotion, Tarlige Tops HP List in June: Intage
  August 23, 2023

• Tecentriq/Cabometyx Combo Extends PFS in Prostate Cancer Trial: Takeda
  August 23, 2023

• Iveric Bio’s AMD Drug Accepted for EMA Review: Astellas
  August 21, 2023

• Opdivo Yet Again Frontrunner, Keytruda Follows in April-June: IQVIA
  August 18, 2023

• Solo Januvia Generic Approval Likely Exploited Patent Loophole, Litigation Possible?
  August 18, 2023

• Takeda Files cTTP Therapy ADAMTS-13 in Japan
  August 18, 2023

• Ex-Takeda Japan Chief Looks to Tackle Social Security Issues via Biz Lobby
  August 17, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 123
• 124
• 125
• 126
• 127
• 128
• 129
• 130
• 131
• …
• Next ›
• 最終 »